{"id":"moxifloxacin-injectable-product","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Tendinitis/tendon rupture"},{"rate":null,"effect":"QT prolongation"},{"rate":null,"effect":"Photosensitivity"},{"rate":null,"effect":"Peripheral neuropathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Moxifloxacin binds to and inhibits DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for bacterial DNA replication and repair. This dual inhibition leads to rapid bactericidal activity against a broad spectrum of aerobic and anaerobic bacteria. The injectable formulation allows for systemic delivery in serious infections where oral administration is not feasible.","oneSentence":"Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:56:01.770Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections (community-acquired pneumonia, complicated skin infections, intra-abdominal infections)"},{"name":"Acute bacterial sinusitis"},{"name":"Acute exacerbation of chronic bronchitis"}]},"trialDetails":[{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":"Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections","enrollment":300},{"nctId":"NCT05398679","phase":"PHASE4","title":"Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":"Endocarditis Infective","enrollment":360},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT03634852","phase":"PHASE4","title":"A Two Chemoprophylaxis Approaches After Phacoemulsification Surgery","status":"COMPLETED","sponsor":"Suzan A Rattan","startDate":"2016-10-01","conditions":"Endophthalmitis Postoperative","enrollment":1000},{"nctId":"NCT03657264","phase":"PHASE1","title":"Cardiac Safety Evaluation of P03277","status":"COMPLETED","sponsor":"Guerbet","startDate":"2017-08-21","conditions":"Healthy Volunteers","enrollment":48},{"nctId":"NCT05079854","phase":"PHASE4","title":"Use Of Intracameral Moxifloxacin For Prophylaxis Of Open Globe Endophthalmitis","status":"UNKNOWN","sponsor":"Federal University of São Paulo","startDate":"2021-10-01","conditions":"Endophthalmitis, Trauma, Corneal","enrollment":100},{"nctId":"NCT03640650","phase":"PHASE4","title":"Economic Impact of Dropless Therapy Versus Usual Care for Cataract Surgery: A Real-World Study.","status":"TERMINATED","sponsor":"PeriPharm","startDate":"2018-08-15","conditions":"Cataract Surgery","enrollment":80},{"nctId":"NCT04545788","phase":"NA","title":"Randomized Controlled Multi-center Short Course Treatment for Rifampicin Resistant Tuberculosis","status":"UNKNOWN","sponsor":"Beijing Chest Hospital","startDate":"2020-08-01","conditions":"Tuberculosis","enrollment":200},{"nctId":"NCT03709927","phase":"PHASE1","title":"4-way Crossover QT Evaluation in Healthy Subjects","status":"COMPLETED","sponsor":"Nabriva Therapeutics AG","startDate":"2018-01-11","conditions":"Cardiac Repolarization in Healthy Subjects","enrollment":41},{"nctId":"NCT02213029","phase":"PHASE1","title":"A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2014-08-28","conditions":"Embryo Transfer","enrollment":33},{"nctId":"NCT02331823","phase":"PHASE4","title":"Research on New Regimens for Retreatment Pulmonary Tuberculosis","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2013-06","conditions":"Reinfection Pulmonary Tuberculosis","enrollment":864},{"nctId":"NCT01546402","phase":"PHASE4","title":"Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2011-05","conditions":"Macular Edema, Cystoid, Vision Disorders, Diabetic Macular Edema","enrollment":20},{"nctId":"NCT00876577","phase":"","title":"VICTOR - Avelox® Intravenous (i.v.) in Acute Exacerbations of Chronic Bronchitis","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-05","conditions":"Chronic Bronchitis, Disease Exacerbation","enrollment":1206}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Moxifloxacin Injectable Product","genericName":"Moxifloxacin Injectable Product","companyName":"Fundacion Clinic per a la Recerca Biomédica","companyId":"fundacion-clinic-per-a-la-recerca-biom-dica","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription. Used for Bacterial infections (community-acquired pneumonia, complicated skin infections, intra-abdominal infections, acute bacterial sinusitis), Hospital-acquired pneumonia, Complicated urinary tract infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}